Antithrombotic effect of SP-8008, a benzoic acid derivative, through the selective inhibition of shear stress-induced platelet aggregation.
Bleeding is one of the most critical adverse effects of antithrombotic drugs and many efforts have been made to discover novel antiplatelet agents without bleeding complications. Shear stress-induced platelet aggregation (SIPA), wherein the interaction of vWF and platelet GP Ib contributes the fundamental initial step, is a promising target to overcome bleeding problem since SIPA occurs only in the pathological conditions. Here, we discovered SP-8008, a novel modulator of vWF-GP Ib interaction and evaluated its antiplatelet/antithrombotic effects. Hundreds of newly synthesized compounds were screened for the effects in high shear stress in a range of in vitro and in vivo experiments. Aggregation, intracellular calcium level, granule secretion and integrin activation were assessed. Molecular modelling using virtual docking, and flow cytometry were used to evaluate the effects on vWF-GP Ib interaction. The in vivo antithrombotic effects were determined by arterial thrombosis and shear stress-specific thrombosis, and transection tail bleeding time was used to evaluate the adverse effect. SP-8008 was a potent inhibitor against SIPA, with IC50 of 1.44 ± 0.09 μM. SP-8008 effectively and broadly blocked shear stress-induced platelet activation events without any significant toxicity. Importantly, SP-8008 was determined to be highly selective against SIPA, effectively interfering with vWF - GP Ib engagement. Most importantly, SP-8008 exerted significant anti-thrombotic effects in vivo in both shear stress-specific, and arterial thrombosis without prolonging bleeding time. Our results demonstrated that SP-8008 can be a novel selective anti-platelet agent with improved safety profile.